[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100485006":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":28,"locations":39,"responsibleParty":58,"collaborators":62,"id":65,"slug":33,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":33,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":33,"studyType":78,"phases":79,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":42,"whyStopped":33,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Hospital Regional de Alta Especialidad del Bajio","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Brentuximab plus PD-1 blocked plus ASCT plus maintenance Brentuximab plus PD-1","EXPERIMENTAL","Brentuximab plus PD-1 blocked x 8 cycles plus ASCT plus maintenance Brentuximab plus PD-1 x 8 cycles",[13],"Drug: Brentuximab Vedotin 50 MG [Adcetris]",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Brentuximab Vedotin 50 MG [Adcetris]","Brentuximab plus blocked PD-1 plus ASCT plus maintenance Brentuximab plus blocked PD-1",[9],[21,22],"Nivolumab","Pembrolizumab",[24],{"name":25,"affiliation":26,"role":27},"Lauro Amador Medina","Hospital regional Alta especialidad Bajío","STUDY_DIRECTOR",[29,35],{"name":30,"role":31,"phone":32,"phoneExt":33,"email":34},"Lauro Fabián Amador, PhD","CONTACT","4772697907",null,"lafab2013@gmail.com",{"name":36,"role":31,"phone":37,"phoneExt":33,"email":38},"JUAN Ojeda Tovar, MD","(477) 267 2000","juan_ojeda82@hotmail.com",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Hospital Regional Alta Especialidad Bajio","RECRUITING","León","Guanajuato","37660","Mexico",{"type":48,"coordinates":49},"Point",[50,51],-101.68253,21.12183,{"lat":51,"lon":50},[54],{"name":55,"role":31,"phone":56,"phoneExt":57,"email":34},"Lauro F Amador, Researcher","477 2672000","1512",{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"PRINCIPAL_INVESTIGATOR","Lauro Fabian Amador Medina","Principal Investigator",[63],{"name":64,"class":6},"Universidad de Guanajuato","100485006",false,"NCT05595447","Treatment Strategy for Relapsed\u002FRefractory Hodgkin Lymphoma","Rescue With Brentuximab Plus PD-1 Blockade Followed by Autotransplantation and Consolidation With Brentuximab Plus PD-1 Blockade in Patients With Relapsed\u002FRefractory Hodgkin Lymphoma: Exploratory Single-arm Analysis","Inclusion Criteria:\n\n1. Relapsed\u002Frefractory Hodgkin lymphoma to ABVD with definition of high risk.\n2. Age ≥ 18 years and ≤ 90 years.\n3. Adequate liver function, defined as:\n\n   * Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN)\n   * Serum aspartate aminotransferase (AST) ≤ 3.0 x ULN\n   * Serum alanine aminotransferase (ALT) ≤ 3.0 x ULN\n4. Adequate renal functions, defined as:\n\n   • Serum creatinine ≤ 1.5x ULN or glomerular filtration rate \\> 50ml\u002Fmin.\n5. ECOG performance status ≤ 3\n6. Women of reproductive potential should have a serum pregnancy test or negative urine.\n7. Prior signature of the informed consent.\n\nExclusion Criteria:\n\n1. Voluntary withdrawal from the study.\n2. Develop grade 3 or 4 toxicity according to the INH scale.\n3. Loss of follow-up",true,"ALL","15 Years","90 Years",{"count":76,"type":77},20,"ESTIMATED","INTERVENTIONAL",[80,81],"PHASE2","PHASE3","The choice of the best second-line therapy in patients with high LH R\u002FR risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.\n\nWhat is the progression-free survival and rate of metabolic responses complete in patients with high-risk R\u002FR HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade\n\n1?",[84,85,86],"Hodgkin Lymphoma","Refractory Hodgkin Lymphoma","Relapsed Hodgkin's Disease, Adult",[88,89,90],"refractory","relapsed","hodgkin lymphoma","2025-03-10",{"date":93,"type":94},"2025-03-12","ACTUAL",{"date":96,"type":94},"2022-10-18",{"date":98,"type":77},"2025-10-18",{"name":5,"class":6},1]